Group | Malaria Vaccines

The RTS,S vaccine candidate produced by GlaxoSmithKline (GSK) Biologicals was tested in a Phase 2 trial completed by Ifakara Health Institute (IHI) and Swiss TPH in 2008. That trial showed that co-administration with EPI-vaccines does not affect the safety and immunogenicity of malaria and EPI vaccines and results in substantial and consistent protection in infants.

A recently completed Phase 3 trial undertaken at the IHI’s Bagamoyo branch, as well as in 10 other African centres and including 16'000 infants and small children, demonstrated a 56% protection rate against malaria episodes and a 34% reduction in severe malaria incidence. Our group is also involved in a number of other trials of vaccine candidates, as well as in the immunological study of the vaccine’s responses.

Marcel Tanner

Marcel Tanner, Professor, PhD, Epidemiologist, MPH

AlKhaldi M et al. Mapping stakeholders of the Palestinian Health Research System: a qualitative study. East Mediterr Health J. 2020;26(3):340-348. DOI: 10.26719/emhj.19.016

Billingsley P.F et al. The equatoguinean malaria vaccine initiative: from the launching of a clinical research platform to malaria elimination planning in Central West Africa. Am J Trop Med Hyg. 2020(in press). DOI: 10.4269/ajtmh.19-0966

Guirou E.A et al. Molecular malaria surveillance using a novel protocol for extraction and analysis of nucleic acids retained on used rapid diagnostic tests. medRxiv. 2020(in press). DOI: 10.1101/2020.02.17.20023960

Otieno L et al. Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa. Vaccine. 2020;38(4):897-906. DOI: 10.1016/j.vaccine.2019.10.077

Penny M.A, Camponovo F, Chitnis N, Smith T.A, Tanner M. Future use-cases of vaccines in malaria control and elimination. Parasite Epidemiol Control. 2020;10:e00145. DOI: 10.1016/j.parepi.2020.e00145